Your browser doesn't support javascript.
loading
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin, Danny; Migden, Michael R; Lim, Annette M; Schmults, Chrysalyne D; Khushalani, Nikhil I; Hughes, Brett G M; Schadendorf, Dirk; Dunn, Lara A; Hernandez-Aya, Leonel; Chang, Anne Lynn S; Modi, Badri; Hauschild, Axel; Ulrich, Claas; Eigentler, Thomas; Stein, Brian; Pavlick, Anna C; Geiger, Jessica L; Gutzmer, Ralf; Alam, Murad; Okoye, Emmanuel; Mathias, Melissa; Jankovic, Vladimir; Stankevich, Elizabeth; Booth, Jocelyn; Li, Siyu; Lowy, Israel; Fury, Matthew G; Guminski, Alexander.
Afiliação
  • Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia danny.rischin@petermac.org.
  • Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lim AM; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Hughes BGM; Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane, Queensland, Australia.
  • Schadendorf D; University Hospital Essen, Essen and German Cancer Consortium, Essen, Germany.
  • Dunn LA; Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Hernandez-Aya L; Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
  • Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA.
  • Modi B; Division of Dermatology, City of Hope, Duarte, California, USA.
  • Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • Ulrich C; Skin Cancer Centre, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Eigentler T; Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen, Germany.
  • Stein B; Adelaide Cancer Centre, Adelaide, South Australia, Australia.
  • Pavlick AC; Department of Medical Oncology, New York University Langone Medical Center, New York, New York, USA.
  • Geiger JL; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Alam M; Department of Dermatology, Northwestern University, Chicago, Illinois, USA.
  • Okoye E; Regeneron Pharmaceuticals, Inc, London, UK.
  • Mathias M; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Jankovic V; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Stankevich E; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Booth J; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA.
  • Li S; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA.
  • Lowy I; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Fury MG; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
J Immunother Cancer ; 8(1)2020 06.
Article em En | MEDLINE | ID: mdl-32554615
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Anticorpos Monoclonais Humanizados / Inibidores de Checkpoint Imunológico Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Anticorpos Monoclonais Humanizados / Inibidores de Checkpoint Imunológico Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália